Back to Search Results

Host-directed therapies for COVID-19.

ImmunoSurgery Unit, Champalimaud Centre for the Unknown, Lisbon, Portugal. I Medizinische Klinik, Johannes Gutenberg University Mainz, Germany. Egas Moniz Higher Education School, Instituto Universitário Egas Moniz, Centro de Investigação Interdisciplinar Egas Moniz (CiiEM, U4585-FCT), Applied Nutrition Studies Group (G.E.N.A.-IUEM), Monte de Caparica, Portugal. Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. Department of Infection, Division of Infection and Immunity, University College London, and National Institutes of Health and Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.

Current opinion in pulmonary medicine. 2021;(3):205-209
Full text from:

Other resources

Abstract

PURPOSE OF REVIEW Severe acute respiratory syndrome coronavirus-2-induced hyperinflammation is a major cause of death or end-organ dysfunction in COVID-19 patients. We review adjunct host-directed therapies (HDTs) for COVID-19 management. RECENT FINDINGS The use of umbilical cord-derived mesenchymal stem cells as HDT for COVID-19 has been shown to be safe in phase 1 and 2 trials. Trials of anti-interleukin-6 receptor antibodies show promising mortality benefit in hospitalized COVID-19 patients. Repurposed drugs and monoclonal antibodies targeting specific cytokines acting on different aspects of the pro- and anti-inflammatory cascades are under evaluation. SUMMARY A range of HDTs shows promise for reducing mortality and improving long term disability in patients with severe COVID-19, and require evaluation in randomized, controlled trials.

Methodological quality

Publication Type : Review

Metadata